(Sharecast News) - Avacta Group reported strong operational progress during 2025 on Tuesday as the clinical-stage biopharmaceutical company advanced its preCISION tumour-activated oncology platform, strengthened its intellectual property estate and secured additional funding to support the transition of a second programme into the clinic in 2026.
The AIM-traded firm said it...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE